In Brief: PLC Systems Heart Laser
This article was originally published in The Gray Sheet
Executive Summary
PLC Systems Heart Laser: Firm submits to FDA 12-month follow-up data for its transmyocardial revascularization device in response to a request by FDA's Circulatory System Devices Panel in its review of the firm's premarket approval application in July ("The Gray Sheet" Aug. 4, p. 7). The panel voted 9-2 to recommend against approval of the device due to lack of follow-up data. PLC expects to provide FDA with additional data by the end of the year. If approved, the system would be the first treatment for patients who do not respond to direct coronary revascularization to reach the U.S. market...
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.